Research·October 22, 2026 at 4:00 PM EDT·1 source
Pfizer details mixed Lyme disease vaccine data
PFE -1.3%VALN
PFE · last 30 trading days+0.6% since the news
News
What happened
- New data from Pfizer and Valneva’s Lyme disease vaccine showed mixed results in two analyses.
- The vaccine’s commercial future remains uncertain following the near-miss in one analysis.
Why it matters
The results may affect development and commercialization decisions for a closely watched healthcare product.
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
Timeline
- EarlierOct 13Beam suggests it can correct mutation; Pfizer to collaborate with Enodia
- First reported by Endpoints NewsOct 22Pfizer details mixed Lyme disease vaccine data
Who is involved
Pfizer details mixed Lyme disease vaccine dataPfizerPFEValnevaVALN
Company
Sources (1)
- Endpoints NewsOct 22Pfizer details mixed Lyme disease vaccine data
Related
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
- Why it matters to youEvery story matched to your watchlist, your contacts and your pipeline.
- Follow developing storiesAn alert, and a push, the moment a story you follow moves.
- Your briefing, read aloudA few minutes each morning with a chapter per story.
- Brief modeSwipe through the day, a 20-second card each.